Friday, 7 February 2014

Cancer drug made for only western countries only, rest of the world youcan help yourself.


#India
#Bayer says new cancer drugs is only for Western patients who can afford it

In a crass yet frank admission, Bayer CEO Marijn Dekkers said the company’s new cancer drug, Nexavar, is not “for Indians,” but “for western patients who can afford it.” The statement came in the wake in a recent ruling by an Indian court that certain life-saving drugs could be produced and distributed at 97% of the brand-name price.

India is not the only country attempting to produce generic versions of patented drugs at a significantly lower cost. South Africa recently caused a row after a similar court ruling allowing for the low-cost local manufacturing and distribution of internationally-patented drugs. In both cases, western capital has threatened punitive actions and even more restricted access to new drugs in the future.

Economically speaking, patents and intellectual property is a type of monopoly capital. When joined with other forms of finance capital, i.e., insurance companies which typically pay the bulk of expensive treatments for those privileged enough to be covered, such monopoly capital allows for the circulation and concentration of capital in the core at the expense of the periphery. Hence, not only do intellectual property rights necessarily restrict access to life-saving medicine for those who cannot afford it, they are part of a system which creates the very conditions whereby the world’s masses are typically poor in the first place.

http://revolution-news.com/bayer-says-new-cancer-drugs-western-patients-can-afford/
#India
#Bayer says new cancer drugs is only for Western patients who can afford it

In a crass yet frank admission, Bayer CEO Marijn Dekkers said the company’s new cancer drug, 


Nexavar, is not “for Indians,” but “for western patients who can afford it.” The statement came in the wake in a recent ruling by an Indian court that certain life-saving drugs could be produced and distributed at 97% of the brand-name price.


India is not the only country attempting to produce generic versions of patented drugs at a significantly lower cost. South Africa recently caused a row after a similar court ruling allowing for the low-cost local manufacturing and distribution of internationally-patented drugs. In both cases, western capital has threatened punitive actions and even more restricted access to new drugs in the future.

Economically speaking, patents and intellectual property is a type of monopoly capital. When joined with other forms of finance capital, i.e., insurance companies which typically pay the bulk of expensive treatments for those privileged enough to be covered, such monopoly capital allows for the circulation and concentration of capital in the core at the expense of the periphery. Hence, not only do intellectual property rights necessarily restrict access to life-saving medicine for those who cannot afford it, they are part of a system which creates the very conditions whereby the world’s masses are typically poor in the first place.

http://revolution-news.com/bayer-says-new-cancer-drugs-western-patients-can-afford/

No comments:

Post a Comment